TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Synthego Stock

Synthego Stock

synthego.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $415.07MM

Synthego, founded in 2012 by Paul and Michael Dabrowski, is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms for science at scale. Synthego is setting out to accelerate CRISPR research, a genome engineering technique that could help cure genetic diseases or even bring back woolly mammoths from extinction. Synthego is headquartered in Redwood City, CA.

Buy or sell Synthego stockLearn more about Synthego IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Synthego, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Synthego’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Synthego.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Synthego investors also invested in these private companies

Menlo Ventures
Wellington Management
8VC
Intel Capital
Ra Capital Management
Founders Fund
SoftBank Investment Advisers
GigaFund
Logos Capital
Chimera Capital
SciFi VC
Pagoda Investment

Team

Management Team

Paul Dabrowski
Co-Founder & Chief Executive Officer
John Tan
Chief Operating Officer & President
Avi Raval
Chief Financial Officer & Chief Business Officer
Robert Deans Ph.D
Chief Scientific Officer

Board Members

Drew Oetting
8VC
Francisco Gimenez Ph.D
8VC
Nathaniel Horwitz
RA Capital Management
Scott Nolan
Founders Fund

Frequently Asked Questions About Synthego’s Stock

plusminus
Can you buy Synthego’s stock?
Synthego is not publicly traded on NYSE or NASDAQ in the U.S. To buy Synthego’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Synthego’s stock?
Yes, you can sell stock of a private company like Synthego. Forge can help you sell your Synthego stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Synthego’s stock price?
Synthego is a privately held company and therefore does not have a public stock price. However, you may access Synthego’s private market stock price with Forge Data.
plusminus
What is Synthego’s stock ticker symbol?
Synthego does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Synthego in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Genomeweb 02/18/2022
People in the News: New Appointments at Quantum-Si, Element Biosciences, Synthego, NeoGenomics, More
Venturebeat 08/26/2020
Synthego raises $100 million for AI-driven gene editing
Synthego, a startup developing a platform for gene editing experiments, has raised an additional $100 million to advance its work.
Geekwire 03/01/2019
In Brief This Week: PerkinElmer, Synthego, Rare Genomics Institute, and More

Trending Companies

Frequently Asked Questions

Updated on: Apr 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.